Asian Spectator


The Times

.

Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer's disease trial

  • Written by PR Newswire Asia - Asian Spectator
Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer's disease trial
  • Late-stage trial in Alzheimer's opens 10 sites in US, with results due in 2025 and 2026
  • Appoints US-based Chief Commercial Officer, Andrew Udell
  • Xanamem's unique ability to control brain cortisol draws widespread coverage in the Australian media.

SYDNEY, Dec. 9, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that the first...

Magazine

Corporate Secretarial Services in Singapore: Annual Compliance, Key Filings, and Common Mistake

Annual compliance in Singapore should not be treated as a once-a-year administrative event. It is an ongoing governance system that depends on accurate records, timely filings, disciplined approvals...

Why Early Protection of Intellectual Assets is Critical

For many businesses, intellectual assets are among the most valuable things they own, yet they're often the last to receive formal legal protection. A brand name or a proprietary process can represe...

Konservasi gaya lama tak efektif: Pemulihan Aceh perlu warga dengan ekonomi yang merawat hutan

shutterstock(Manthofana/Shutterstock)● Peminggiran warga dari konservasi hutan Lingga Isaq menjadi salah satu faktor yang memperparah dampak bencana.● Pertanian monokultur dan tambang emas...

hacklink hack forum hacklink film izle hacklink z-libraryMeritbetMeritbetjojobet giriş爱思助手下载telegram下载matbetgrandpashabetgrandpashabet twiter xmeritbettelegram webroyalbet girişcasibomjojobetmeritkingbodrum escortcratosroyalbetagen bolagrandpashabetgrandpashabetjojobetcasibomholiganbet